BioSpace News Archive

Innovent Biologics, Inc. today announced that, five products (including new indications) of the company have been included in the updated National Reimbursement Drug List (2022 Version) (“NRDL”).

NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided an update on the efforts to expand access to the Company’s PainShield product.

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced initial results from a pharmacokinetic (PK) substudy within the phase III un-blinded randomized control TIGeR-PaC clinical trial to be presented at the ASCO GI Cancers Symposium in San Francisco on January 19-21, 2023.

Net Medical announced it has been invited to participate with Accorto Regulatory Solutions at the Medical Design & Manufacturing trade show in Anaheim, CA on February 7-9, 2023.

BriaCell Therapeutics Corp is pleased to announce that it has received agreement and positive feedback from its End of Phase II meeting with the FDA regarding BriaCell’s lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor (under Fast Track designation), in advanced metastatic breast cancer.

Aldevron®, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, launches Eureca-V™ Nuclease, the wild-type MAD7® CRISPR Type-V nuclease, licensed from Inscripta®, at Research Grade today with GMP to follow.

Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

The award-winning CeCe Migraine Management app now offers users an unprecedented level of insight into their migraine treatments with the CEFALY Connected device.

New research reveals that precision prescribing using genetic testing has finally reached a global tipping point for adoption.

Ayana Bio, the plant cell technology company making sustainable bioactives for consumer products, has pledged $3 million to accelerate the production of cacao bioactives through cellular cultivation.